BRIEF published on 12/16/2025 at 21:23, 1 day 17 hours ago ABIONYX Pharma Announces a Capital Increase Fundraising Capital Increase Biopharmaceutical ABIONYX Pharma Sepsis
BRIEF published on 12/16/2025 at 21:23, 1 day 17 hours ago ABIONYX Pharma Announces €1.8 Million Capital Increase Capital Increase Subscription Rights Euronext Listing ABIONYX Pharma Financial Visibility
PRESS RELEASE published on 12/16/2025 at 21:18, 1 day 18 hours ago Inside Information / Other news releases ABIONYX Pharma launches €1.8m capital increase with removal of preferential subscription rights, subscription price at 3.10 euros for new shares, extending financial visibility until 2026 Capital Increase Biopharma Preferential Subscription Rights ABIONYX Pharma Financial Visibility
BRIEF published on 12/05/2025 at 18:05, 12 days 21 hours ago ABIONYX Reports Monthly Voting Rights and Share Data Euronext Paris Share Capital Voting Rights AMF Regulations ABIONYX Pharma
PRESS RELEASE published on 12/05/2025 at 18:00, 12 days 21 hours ago Inside Information / Other news releases ABIONYX Pharma discloses monthly statement of total voting rights and shares as per French regulations. Company focused on innovative medicines in rare diseases Shares French Regulations Total Voting Rights ABIONYX Pharma Innovative Medicines
BRIEF published on 11/25/2025 at 18:38, 22 days 20 hours ago ABIONYX Pharma Releases Q3 2025 Business Update Revenue Financial Update ABIONYX Pharma Q3 2025 Sepsis Research
PRESS RELEASE published on 11/25/2025 at 18:33, 22 days 20 hours ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
BRIEF published on 11/12/2025 at 07:05, 1 month 6 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 1 month 27 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 1 month 27 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
Published on 12/18/2025 at 15:00, 21 minutes ago Vox Royalty Acquires Feasibilty-Stage Stockman Copper-Gold Royalty in Australia
Published on 12/18/2025 at 14:31, 50 minutes ago Worksport Reports Highest Monthly Revenue in Company History
Published on 12/18/2025 at 14:00, 1 hour 21 minutes ago Route1 Announces Provisional Patent Application
Published on 12/18/2025 at 14:00, 1 hour 21 minutes ago LQR House Announces $6.52 Million Registered Direct Offering
Published on 12/18/2025 at 14:00, 1 hour 21 minutes ago Trifecta Gold Hits 1,465 g/t Silver Over 1.97 Metres at Rye Project, Yukon
Published on 12/18/2025 at 15:08, 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 12/18/2025 at 15:08, 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/18/2025 at 15:07, 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc
Published on 12/18/2025 at 15:06, 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: Unite Group plc, The
Published on 12/18/2025 at 15:06, 14 minutes ago Original-Research: Energiekontor AG (von First Berlin Equity Research GmbH): Buy
Published on 12/17/2025 at 20:39, 18 hours 41 minutes ago Aeroports de Paris SA | 2026 Airport charges in Paris
Published on 12/17/2025 at 18:00, 21 hours 21 minutes ago Outstanding Shares and Voting Rights Statement at 30 November 2025
Published on 12/17/2025 at 17:51, 21 hours 29 minutes ago Mr.Bricolage: Completion of the simplification of the Mr.Bricolage Group’s shareholding structure
Published on 12/17/2025 at 17:50, 21 hours 31 minutes ago The Council of Paris approves the selection of Dalkia/Eiffage/RATP Solutions Ville consortium for Paris district heating network concession renewal.
